Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

Analytical and Bioanalytical Chemistry

Volumn 400, Issue 2, 2011, Pages 423-433

  MacWan, Joyce S ^a   Ionita, Ileana A ^a   Dostalek, Miroslav ^a   Akhlaghi, Fatemeh ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Assay; Atorvastatin; Concentration; Lactones; LC MS MS; Metabolites; Pharmacokinetics

Indexed keywords

ANALYTES; ATORVASTATIN; CALIBRATION CURVES; CHROMATOGRAPHIC SEPARATIONS; CLINICAL STUDY; CONCENTRATION; CONCENTRATION RANGES; EXTRACTION RECOVERY; GLACIAL ACETIC ACID; HUMAN PLASMAS; HYDROXY METABOLITES; INTERNAL STANDARDS; LACTONES; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTITATIONS; MOBILE PHASE; MULTIPLE REACTION MONITORING; PHENYL COLUMNS; POSITIVE ELECTROSPRAY IONIZATION; PROTEIN PRECIPITATION; RAPID METHOD; SENSITIVE ASSAY; STABILITY STUDY; WATER SLURRY;

ACETIC ACID; ACETONITRILE; BIOMOLECULES; CHEMICAL ANALYSIS; DEUTERIUM; ELECTROSPRAY IONIZATION; LIQUIDS; MASS SPECTROMETRY; METABOLISM; METABOLITES; METHANOL; ORGANIC SOLVENTS; PHARMACOKINETICS; PLASMA (HUMAN); PLASMA STABILITY;

LIQUID CHROMATOGRAPHY;

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LACTONE; PYRROLE DERIVATIVE;

ARTICLE; BLOOD; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; METABOLISM; METHODOLOGY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTICHOLESTEREMIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPTANOIC ACIDS; HUMANS; LACTONES; LIMIT OF DETECTION; PYRROLES; TANDEM MASS SPECTROMETRY;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS;

EID: 79954634266     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-011-4804-y     Document Type: Article

References (36)

1. JL Breslow 1997 Cardiovascular disease burden increases, NIH funding decreases Nat Med 3 600 601 10.1038/nm0697-600 1:CAS:528:DyaK2sXjsFKktbo%3D (Pubitemid 27264961)
2. JK Xu D Kochapek SL Murphy B Tejada-Vera 2010 Deaths: final data for 2007 Natl Vital Stat Rep 58 1 73
3. H Lennernas 2003 Clinical pharmacokinetics of atorvastatin Clin Pharmacokinet 42 1141 1160 10.2165/00003088-200342130-00005 (Pubitemid 37357650)
4. NM Schuster MA Rogers LF McMahon Jr 2010 Using search engine query data to track pharmaceutical utilization: a study of statins Am J Manag Care 16 e215 e219
5. W Jacobsen B Kuhn A Soldner G Kirchner KF Sewing PA Kollman LZ Benet U Christians 2000 Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab Dispos 28 1369 1378 1:CAS:528:DC%2BD3cXnsFOlsbs%3D
6. AS Kearney LF Crawford SC Mehta GW Radebaugh 1993 The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 Pharm Res 10 1461 1465 10.1023/A:1018923325359 1:CAS:528:DyaK2cXjsl2ntQ%3D%3D (Pubitemid 23302663)
7. T Kantola KT Kivisto PJ Neuvonen 1998 Effect of itraconazole on the pharmacokinetics of atorvastatin Clin Pharmacol Ther 64 58 65 10.1016/S0009-9236(98)90023-6 1:CAS:528:DyaK1cXltlarsrk%3D (Pubitemid 28377331)
8. A Poli 2007 Atorvastatin: pharmacological characteristics and lipid-lowering effects Drugs 67 Suppl 1 3 15 10.2165/00003495-200767001-00002 1:CAS:528:DC%2BD1cXmsFKlug%3D%3D (Pubitemid 350114591)
9. M Schachter 2005 Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 117 125 10.1111/j.1472-8206. 2004.00299.x 1:CAS:528:DC%2BD2MXhsVCms7Y%3D (Pubitemid 40204354)
10. PD Thompson P Clarkson RH Karas 2003 Statin-associated myopathy JAMA 289 1681 1690 10.1001/jama.289.13.1681 1:CAS:528:DC%2BD3sXisF2is7k%3D (Pubitemid 37430274)
11. M Hermann MP Bogsrud E Molden A Asberg BU Mohebi L Ose K Retterstol 2006 Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy Clin Pharmacol Ther 79 532 539 10.1016/j.clpt.2006.02.014 1:CAS:528: DC%2BD28Xltl2msrs%3D (Pubitemid 43833450)
12. IB Skottheim A Gedde-Dahl S Hejazifar K Hoel A Asberg 2008 Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro Eur J Pharm Sci 33 317 325 10.1016/j.ejps.2007. 12.009 1:CAS:528:DC%2BD1cXktlCqu7Y%3D
13. N Erk 2004 Development of electrochemical methods for determination of atorvastatin and analytical application to pharmaceutical products and spiked human plasma Crit Rev Anal Chem 34 1 7 10.1080/10408340490273717 1:CAS:528:DC%2BD2cXhvVOmsL8%3D (Pubitemid 38431395)
14. TG Altuntas N Erk 2004 Liquid chromatographic determination of atorvastatin in bulk drug, tablets, and human plasma J Liq Chromatogr Related Technol 27 83 93 10.1081/JLC-120027087 1:CAS:528:DC%2BD2cXlsFentg%3D%3D (Pubitemid 38249768)
15. G Bahrami B Mohammadi S Mirzaeei A Kiani 2005 Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection J Chromatogr B Analyt Technol Biomed Life Sci 826 41 45 10.1016/j.jchromb.2005.08.008 1:CAS:528:DC%2BD2MXhtFSmtrvF (Pubitemid 41446432)
16. HR Shen ZD Li MK Zhong 2006 HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system Pharmazie 61 18 20 1:CAS:528:DC%2BD28XmtVOksw%3D%3D
17. A Zarghi A Shafaati SM Foroutan A Khoddam 2005 A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies Arzneimittelforschung 55 451 454 1:CAS:528:DC%2BD2MXpvFKitrc%3D (Pubitemid 41190747)
18. YY Shum N Huang G Walter A Black C Sekerke T Chang LR Whitfield 1998 Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices Ther Drug Monit 20 41 49 10.1097/00007691-199802000-00008 1:CAS:528:DyaK1cXhtVyrs7Y%3D (Pubitemid 28110100)
19. RJ Valesky L Liu DG Musson JJ Zhao 2008 Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection J pharmacol toxicol methods 57 61 69 10.1016/j.vascn.2007.06.002 1:CAS:528:DC%2BD2sXhtlGgtb7L (Pubitemid 350137779)
20. CK Van Pelt TN Corso GA Schultz S Lowes J Henion 2001 A four-column parallel chromatography system for isocratic or gradient LC/MS analyses Anal Chem 73 582 588 10.1021/ac0006876
21. XS Miao CD Metcalfe 2003 Determination of pharmaceuticals in aqueous samples using positive and negative voltage switching microbore liquid chromatography/electrospray ionization tandem mass spectrometry J Mass Spectrom 38 27 34 10.1002/jms.394 1:CAS:528:DC%2BD3sXovVyjsg%3D%3D (Pubitemid 36157754)
22. V Borek-Dohalsky J Huclova B Barrett B Nemec I Ulc I Jelinek 2006 Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study Anal Bioanal Chem 386 275 285 10.1007/s00216-006-0655-3 1:CAS:528:DC%2BD28XptVegtr8%3D (Pubitemid 44327024)
23. WW Bullen RA Miller RN Hayes 1999 Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma J Am Soc Mass Spectrom 10 55 66 10.1016/S1044- 0305(98)00118-4 1:CAS:528:DyaK1MXosl2j (Pubitemid 34450236)
24. D Guillen F Cofan E Ros O Millan M Cofan A Rimola M Brunet 2009 Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry Anal Bioanal Chem 394 1687 1696 10.1007/s00216-009-2852-3 1:CAS:528:DC%2BD1MXntVSgtrg%3D
25. M Hermann H Christensen JL Reubsaet 2005 Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS Anal Bioanal Chem 382 1242 1249 10.1007/s00216-005-3266-5 1:CAS:528:DC%2BD2MXlvVCitrw%3D (Pubitemid 40983114)
26. M Jemal Z Ouyang BC Chen D Teitz 1999 Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry Rapid Commun Mass Spectrom 13 1003 1015 10.1002/(SICI)1097- 0231(19990615)13:11<1003::AID-RCM597>3.0.CO;2-L 1:CAS:528: DyaK1MXjslentbc%3D (Pubitemid 29257202)
27. D Liu J Jiang H Zhou P Hu 2008 Quantitative determination of atorvastatin and para-hydroxy atorvastatin in human plasma by LC-MS-MS J Chromatogr Sci 46 862 866 1:CAS:528:DC%2BD1cXhtlaisL%2FP
28. L Ma J Dong XJ Chen GJ Wang 2007 Development and validation of atorvastatin by LC-ESI-MS and application in bioequivalence research in healthy chinese volunteers Chromatographia 65 737 741 10.1365/s10337-007-0236-4 1:CAS:528:DC%2BD2sXns1OltL4%3D (Pubitemid 46883631)
29. RV Nirogi VN Kandikere M Shukla K Mudigonda S Maurya R Boosi Y Anjaneyulu 2006 Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard Biomed Chromatogr 20 924 936 10.1002/bmc.622 1:CAS:528:DC%2BD28XhtVWnur3M (Pubitemid 44430552)
30. L Novakova H Vlckova D Satinsky P Sadilek D Solichova M Blaha V Blaha P Solich 2009 Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin J Chromatogr B Analyt Technol Biomed Life Sci 877 2093 2103 10.1016/j.jchromb. 2009.05.052 1:CAS:528:DC%2BD1MXnsl2htL0%3D
31. US Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioanalytical Method Validation (2001) See http://www.fda.gov/cder/guidance/ 4252fnl.htm. Accessed Feb 2011
32. T Prueksaritanont R Subramanian X Fang B Ma Y Qiu JH Lin PG Pearson TA Baillie 2002 Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab Dispos 30 505 512 10.1124/dmd.30.5.505 1:CAS:528:DC%2BD38Xjt12ls74%3D (Pubitemid 34456970)
33. S Billecke D Draganov R Counsell P Stetson C Watson C Hsu BN La Du 2000 Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters Drug Metab Dispos 28 1335 1342 1:CAS:528:DC%2BD3cXnsFOlsb8%3D
34. S Amberg AS Loevenhart 1908 Further observations on the inhibiting effect of fluorides on the action of lipase, together with a method for the detection of fluorides in food products J Biol Chem 4 149 164 1:CAS:528: DyaD1cXhtFGksQ%3D%3D
35. S Wang M Cyronak E Yang 2007 Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma J Pharm Biomed Anal 43 701 707 10.1016/j.jpba.2006.08.010 1:CAS:528: DC%2BD2sXhsFaqug%3D%3D (Pubitemid 46001699)
36. G Zhang CE Wujcik 2009 Overcoming ionization effects through chromatography: a case study for the ESI-LC-MS/MS quantitation of a hydrophobic therapeutic agent in human serum using a stable-label internal standard J Chromatogr B Analyt Technol Biomed Life Sci 877 2003 2010 10.1016/j.jchromb. 2009.05.031 1:CAS:528:DC%2BD1MXnsl2ht74%3D